The US FDA adopted the advice of patient advocates in developing draft guidance on how to submit proposed guidances relating to patient experience data. The document lists other ways that external groups can help advance patient-focused drug development, such as by developing a patient registry, conducting natural history studies or collaborating with sponsors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?